$KIDS
ORTHOPEDIATRICS CORP Stock $kids

$kids Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000142545018000070 Filed on May 15, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q1
Revenue	$15.08M	$12.09M	$9.762M
YoY Change	27.75%	23.89%	20.95%
Cost Of Revenue	$3.807M	$3.175M	$2.347M
YoY Change	23.2%	35.28%	-60.78%
Gross Profit	$11.27M	$8.919M	$7.415M
YoY Change	29.36%	20.28%	255.29%
Gross Profit Margin	74.75%	73.75%	75.96%
Selling, General & Admin	$12.28M	$12.10M	$7.565M
YoY Change	40.75%	59.89%	8.69%
% of Gross Profit	108.92%	135.62%	102.02%
Research & Development	$1.115M	$1.218M	$687.0K
YoY Change	66.92%	77.29%	34.71%
% of Gross Profit	9.89%	13.66%	9.27%
Depreciation & Amortization	$720.0K	$681.0K	$498.0K
YoY Change	22.03%	36.75%	10.67%
% of Gross Profit	6.39%	7.64%	6.72%
Operating Expenses	$13.39M	$13.31M	$8.252M
YoY Change	42.61%	61.34%	10.47%
Operating Profit	-$2.120M	-$4.395M	-$837.0K
YoY Change	213.15%	425.09%	-43.67%
Interest Expense	-$560.0K	-$550.0K	-$450.0K
YoY Change	-13.85%	22.22%	45.16%
% of Operating Profit
Other Income/Expense, Net	-$572.0K	-$605.0K	-$448.0K
YoY Change	-197.11%	35.04%	4380.0%
Pretax Income	-$2.690M	-$5.000M	-$1.290M
YoY Change	111.81%	287.6%	-28.73%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.692M	-$5.000M	-$1.285M
YoY Change	112.64%	289.11%	-28.81%
Net Earnings / Revenue	-17.86%	-41.34%	-13.16%
Basic Earnings Per Share
Diluted Earnings Per Share	-$214.3K	-$414.3K	-$107.1K
COMMON SHARES
Basic Shares Outstanding	12.77M shares	12.77M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$26.50M	$34.60M	$2.400M
YoY Change	1052.17%	1341.67%	71.43%
Cash & Equivalents	$26.51M	$34.59M	$2.446M
Short-Term Investments
Other Short-Term Assets	$1.100M	$1.100M	$400.0K
YoY Change	10.0%	175.0%	-75.0%
Inventory	$25.40M	$23.40M	$16.60M
Prepaid Expenses
Receivables	$9.755M	$6.838M	$3.900M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$62.74M	$65.95M	$23.40M
YoY Change	117.83%	181.83%	7.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.77M	$12.28M	$7.300M
YoY Change	55.73%	68.22%	14.06%
Goodwill
YoY Change
Intangibles	$2.340M	$2.414M
YoY Change
Long-Term Investments
YoY Change
Other Assets			$1.500M
YoY Change			36.36%
Total Long-Term Assets	$15.11M	$14.69M	$10.40M
YoY Change	34.91%	41.29%	22.35%
TOTAL ASSETS
Total Short-Term Assets	$62.74M	$65.95M	$23.40M
Total Long-Term Assets	$15.11M	$14.69M	$10.40M
Total Assets	$77.85M	$80.64M	$33.80M
YoY Change	94.61%	138.59%	11.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.455M	$7.197M	$5.700M
YoY Change	-10.57%	26.26%	119.23%
Accrued Expenses	$3.200M	$2.300M	$1.700M
YoY Change	33.33%	35.29%	6.25%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$115.0K	$114.0K	$100.0K
YoY Change	15.0%	14.0%	0.0%
Total Short-Term Liabilities	$10.49M	$10.57M	$8.800M
YoY Change	0.87%	20.11%	20.55%
LONG-TERM LIABILITIES
Long-Term Debt	$25.30M	$25.32M	$19.90M
YoY Change	-0.4%	27.23%	53.08%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$25.30M	$25.32M	$19.90M
YoY Change	-0.4%	27.23%	53.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.49M	$10.57M	$8.800M
Total Long-Term Liabilities	$25.30M	$25.32M	$19.90M
Total Liabilities	$35.79M	$35.89M	$28.70M
YoY Change	-0.03%	25.05%	41.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$110.8M	-$108.1M
YoY Change
Common Stock	$2.000K	$2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$42.06M	$44.75M	$5.000M
YoY Change
Total Liabilities & Shareholders Equity	$77.85M	$80.64M	$33.80M
YoY Change	94.61%	138.59%	11.92%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$2.692M	-$5.000M	-$1.285M
YoY Change	112.64%	289.11%	-28.81%
Depreciation, Depletion And Amortization	$720.0K	$681.0K	$498.0K
YoY Change	22.03%	36.75%	10.67%
Cash From Operating Activities	-$6.640M	-$5.033M	-$5.000K
YoY Change	57.35%	100560.0%	-99.69%
INVESTING ACTIVITIES
Capital Expenditures	-$1.420M	$2.771M	$1.332M
YoY Change	-5.96%	108.03%	-280.0%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$1.420M	-$2.930M	-$1.632M
YoY Change	-5.96%	79.53%	120.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$28.00K	$26.00K
YoY Change		7.69%
Cash From Financing Activities	-30.00K	-$28.00K	$2.474M
YoY Change	-100.54%	-101.13%	-2161.67%
NET CHANGE
Cash From Operating Activities	-6.640M	-$5.033M	-$5.000K
Cash From Investing Activities	-1.420M	-$2.930M	-$1.632M
Cash From Financing Activities	-30.00K	-$28.00K	$2.474M
Net Change In Cash	-8.090M	-$7.991M	$837.0K
YoY Change	3945.0%	-1054.72%	-133.61%
FREE CASH FLOW
Cash From Operating Activities	-$6.640M	-$5.033M	-$5.000K
Capital Expenditures	-$1.420M	$2.771M	$1.332M
Free Cash Flow	-$5.220M	-$7.804M	-$1.337M
YoY Change	92.62%	483.69%	50.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-5000000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42582000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34591000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	837000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7991000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	135000	USD
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	217000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	150424000	USD
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	152601000	USD
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12621781	shares
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	143000	USD
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12770796	shares
CY2018Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	131000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4618657	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12621781	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12770796	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	881846	shares
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	ORTHOPEDIATRICS CORP
CY2017Q4	us-gaap	Assets Assets	82301000	USD
CY2018Q1	us-gaap	Assets Assets	80643000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	69561000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1285000	USD
CY2018Q1	kids	Classof Warrantor Right Exercised ClassofWarrantorRightExercised	0	shares
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4918000	USD
CY2017Q1	us-gaap	Cost Of Revenue CostOfRevenue	2347000	USD
CY2018Q1	us-gaap	Cost Of Revenue CostOfRevenue	3175000	USD
CY2018Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2018Q1	kids	Classof Warrantor Right Term ClassofWarrantorRightTerm	P10Y
CY2018Q1	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitation	16200000	USD
CY2018Q1	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimit	1062000	USD
CY2018Q1	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit Increase OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimitIncrease	2302000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	65949000	USD
CY2018Q1	kids	Researchand Development Arrangement Contractto Performfor Others Minimum Annual Royalty Payment ResearchandDevelopmentArrangementContracttoPerformforOthersMinimumAnnualRoyaltyPayment	500000	USD
CY2017Q1	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	567000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	498000	USD
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001425450
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12772296	shares
CY2018Q1	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	304000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5495000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	681000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.55
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	7197000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2905000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1609000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2446000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5603000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6838000	USD
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2313000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2089000	USD
CY2017Q1	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2018Q1	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	283000	USD
CY2017Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	260000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	-198000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	1235000	USD
CY2018Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	260000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2349000	USD
CY2018Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2414000	USD
CY2017Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-445000	USD
CY2018Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-552000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	445000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2154000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2167000	USD
CY2018Q1	us-gaap	Interest Paid InterestPaid	552000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	34806000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1702000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-578000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	35889000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82301000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-600000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	0	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	80643000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9467000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10570000	USD
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	25452000	USD
CY2017Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2018Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2018Q1	us-gaap	Long Term Debt LongTermDebt	25433000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	113000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3373000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6017000	USD
CY2018Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	114000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	25339000	USD
CY2018Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	25319000	USD
CY2017Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	3921000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	7415000	USD
CY2018Q1	us-gaap	Gross Profit GrossProfit	8919000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2711000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5000000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-82000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	191000	USD
CY2018Q1	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	3930000	USD
CY2017Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	21418000	USD
CY2018Q1	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	21389000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2474000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-28000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1632000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2930000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5033000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-1285000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2711000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5000000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-448000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	29.89
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-605000	USD
CY2018Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	8252000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	13314000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-837000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4395000	USD
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	70335000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2018Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	82000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	82000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	954000	USD
CY2018Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	946000	USD
CY2017Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	3000	USD
CY2018Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	53000	USD
CY2017Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	300000	USD
CY2018Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	159000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1332000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2771000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	831000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1114000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2500000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10391000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12280000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	26000	USD
CY2018Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	28000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	687000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1218000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103066000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-108066000	USD
CY2017Q1	us-gaap	Revenues Revenues	9762000	USD
CY2018Q1	us-gaap	Revenues Revenues	12094000	USD
CY2017Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4192000	USD
CY2018Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6079000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	339000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2177000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	36234	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	27.61
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	176959	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	140725	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	29.42
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y2M12D
CY2018Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2177000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	47495000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	44754000	USD
CY2017Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	335000	USD
CY2017Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1426000	USD
CY2018Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	0	USD
CY2017Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1426000	USD
CY2018Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2016Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	7000000	shares
CY2017Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5446978	shares
CY2017Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2018Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1744356	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12073776	shares
CY2018Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BUSINESS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></font><font style="font-family:Arial;font-size:10pt;">, PediPlates</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></font><font style="font-family:Arial;font-size:10pt;">, Cannulated Screws, PediFlex</font><font style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Arial;font-size:6.5pt;"> </font><font style="font-family:Arial;font-size:10pt;">nail, PediNail</font><font style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Arial;font-size:10pt;">, PediLoc</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></font><font style="font-family:Arial;font-size:10pt;"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, Bandloc and Pediguard, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand permitting us to sell under an agency model direct to local hospitals in these countries. Operations began in the United Kingdom on April 3, 2017, in Australia on May 1, 2017 and in New Zealand on July 1, 2017. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On October 12, 2017, we completed an initial public offering ("IPO") of our common stock, in which we issued and sold </font><font style="font-family:Arial;font-size:10pt;">4.6 million</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock at a public offering price of </font><font style="font-family:Arial;font-size:10pt;">$13.00</font><font style="font-family:Arial;font-size:10pt;"> per share for aggregate gross proceeds of </font><font style="font-family:Arial;font-size:10pt;">$59,800</font><font style="font-family:Arial;font-size:10pt;">. We received approximately </font><font style="font-family:Arial;font-size:10pt;">$46,900</font><font style="font-family:Arial;font-size:10pt;"> in net proceeds after deducting </font><font style="font-family:Arial;font-size:10pt;">$4,200</font><font style="font-family:Arial;font-size:10pt;"> of underwriting discounts and commissions, paying approximately </font><font style="font-family:Arial;font-size:10pt;">$2,700</font><font style="font-family:Arial;font-size:10pt;"> of offering costs and paying approximately </font><font style="font-family:Arial;font-size:10pt;">$6,000</font><font style="font-family:Arial;font-size:10pt;"> of Series B dividends. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our largest investor is Squadron Capital LLC (“Squadron”), a family office firm headquartered near Hartford, Connecticut.</font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Preparation of the condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in the condensed consolidated financial statements.</font></div></div>

Files In Submission

Name	View Source	Status
0001425450-18-000070-index-headers.html	Edgar Link	pending
0001425450-18-000070-index.html	Edgar Link	pending
0001425450-18-000070.txt	Edgar Link	pending
0001425450-18-000070-xbrl.zip	Edgar Link	pending
exhbit322-cfocertification.htm	Edgar Link	pending
exhibit311-ceocertification.htm	Edgar Link	pending
exhibit312-cfocertification.htm	Edgar Link	pending
exhibit321-ceocertification.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
kids-20180331.xml	Edgar Link	completed
kids-20180331.xsd	Edgar Link	pending
kids-20180331_cal.xml	Edgar Link	unprocessable
kids-20180331_def.xml	Edgar Link	unprocessable
kids-20180331_lab.xml	Edgar Link	unprocessable
kids-20180331_pre.xml	Edgar Link	unprocessable
q1201810-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KIDS
ORTHOPEDIATRICS CORP Stock $kids

2018 Q2 Form 10-Q Financial Statement

#000142545018000070 Filed on May 15, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS ORTHOPEDIATRICS CORP Stock $kids

2018 Q2 Form 10-Q Financial Statement

#000142545018000070 Filed on May 15, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS
ORTHOPEDIATRICS CORP Stock $kids